Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

33.3%

1 terminated/withdrawn out of 3 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
2(66.7%)
Phase 1
1(33.3%)
3Total
Phase 2(2)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT05942911Phase 2Terminated

Safety and Effect on Pain and Function According to RAPID-3 of IHL-675A in Patients With Rheumatoid Arthritis

Role: lead

NCT06146101Phase 2Active Not Recruiting

RePOSA-Revealing the Efficacy of IHL-42X Use in Patients With OSA

Role: lead

NCT05857384Phase 1Completed

Bioavailability, Bioequivalence and Tolerability of IHL-42X Compared to the Reference Drugs

Role: lead

All 3 trials loaded